Pros and cons of GLP-1 agonists for weight loss

When weight has been stubborn despite your best efforts with food and movement, GLP‑1 receptor agonists can offer an additional therapeutic option rather than yet another “diet.” It is still essential, though, to understand both the potential benefits and the limitations so you can decide whether this route fits your health goals, medical history, and budget (especially in countries where you have to pay out of pocket for the drugs).

Pros of GLP‑1 weight‑loss medications

• Effective, clinically tested weight loss


  Most people treated at adequate doses, alongside lifestyle support, lose roughly 10–15% of their starting body weight over time, with some tirzepatide studies reporting average losses close to 20% at the highest maintenance doses. This level of reduction is often enough to improve blood pressure, blood sugars, joint pain, sleep apnoea and other weight‑related conditions.

• Improved metabolic health


  GLP‑1 drugs mimic a gut hormone that helps the pancreas release more insulin when blood sugar is high, reduces glucagon, and slows stomach emptying. Together, these effects can lower HbA1c in people with type 2 diabetes, reduce insulin resistance, and contribute to favourable changes in blood pressure and cholesterol.

• Appetite regulation and fewer cravings


  By acting on receptors in the brain and gut, GLP‑1 agonists reduce hunger signals and increase satiety. Many people describe less “food noise,” fewer intense cravings, and feeling satisfied with smaller portions. This can make it easier to maintain new habits when motivation and willpower are under strain.

Cons and uncertainties

• High ongoing cost


  Out‑of‑pocket costs are substantial in many countries. Where weight‑loss use is not widely funded, monthly expenses can reach several hundred pounds or dollars. Some manufacturer schemes and structured programmes can reduce this, but long‑term affordability remains a key consideration.

• Likely need for long‑term treatment


  Current evidence suggests that, for most people, stopping the medication leads to partial or complete weight regain over the following months unless very strong lifestyle structures are in place. In practice, that means many will need prolonged or indefinite treatment to maintain the magnitude of their weight loss, with both medical and financial implications.

• Common short‑term side‑effects

  When starting or increasing the dose, it is very common to experience nausea, vomiting, diarrhoea or constipation, bloating, abdominal discomfort, reduced appetite, fatigue, dizziness, headaches, or mild reactions at the injection site. These symptoms often ease over time and with careful dose escalation, but in some people, they can persist or be troublesome enough to affect daily life.

• Longer‑term risks and knowledge gaps


  As with any rapid weight‑loss approach, a proportion of the weight lost on GLP‑1s comes from lean mass, including muscle. There is concern that this muscle is not fully recovered when weight returns, which may affect strength and metabolism. Sustained weight loss can also accelerate bone mineral density loss, potentially increasing fracture risk, particularly in older adults. Rare but serious events such as pancreatitis, gallbladder problems, kidney injury and specific thyroid changes have been reported, and the very long‑term effects on the brain, eyes and other organs are still being studied.

How do GLP‑1s compare with surgical or endoscopic options?

• Bariatric surgery


  Procedures such as gastric bypass and sleeve gastrectomy typically result in an average 20–30% total body‑weight loss. They can induce remission of type 2 diabetes and other conditions in a substantial proportion of patients. Although the upfront cost of surgery is high, long‑term analyses often find it more cost‑effective than many years of high‑priced medication for people with severe obesity and multiple comorbidities.

• Endoscopic approaches
Intragastric balloons and other endoscopic devices are less invasive and usually have lower initial costs. They tend to produce around 10–15% weight loss while in place. Still, the effect is often temporary, and weight regain is typical once the device is removed unless substantial lifestyle changes are maintained.

Making a personalised decision

GLP‑1 agonists have transformed obesity treatment, but they are not a universal solution, and they are not appropriate for everyone. Ideally, the decision to start them should be made in partnership with a clinician who can look at:

• Your medical history, current diagnoses and other medications.

• Your treatment goals (for example: diabetes control, joint relief, fertility, cardiovascular risk, quality of life).

• Financial and practical considerations, including how long you could realistically stay on treatment.

• Your willingness and ability to work on nutrition, movement, sleep and stress alongside any medication.

Whether you move forward with GLP‑1 medication, explore surgical options, consider other drug classes, or focus on an intensive lifestyle‑first approach, the most critical step is to choose a plan that supports your health in a sustainable, compassionate way—rather than chasing short‑term results at any cost.